No Data
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 11, 2025 /PRNewswire/
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
WUXI BIO has launched a new microbial expression platform EffiX to empower high-yield recombinant proteins and plasmids.
- EffiX aims to meet the market's demand for high-yield, stable, non-solvent-based E. coli expression systems, providing comprehensive solutions for the development and production of non-antibody recombinant proteins and plasmid DNA for Global clients. - EffiX can achieve high yields across various types of molecules, with non-antibody recombinant protein yields exceeding 15 grams per liter and plasmid DNA yields exceeding 1 gram per liter. Hangzhou, March 4, 2025 /PR Newswire/ -- A global leader in contract research, development, and manufacturing (CRDMO) services.
WuXi Biologics Launches EffiX Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks
WUXI BIO has once again passed the Japan PMDA GMP inspection, accumulating 42 passes through Global Pharmaceutical regulatory inspections.
WUXI BIO announced on February 27, 2025, in Wuxi / PR Newswire / -- that the company’s biopharmaceutical raw material production plants (MFG2 and MFG5) at its Wuxi base have again passed the GMP inspection by the Japan Pharmaceutical and Medical Devices Agency (PMDA). The company achieved a zero-defect result in this on-site inspection covering facility quality systems and the entire production process, showcasing its outstanding capability to meet Global regulatory requirements. So far, WUXI BIO has successfully accumulated.
